DISEASE CHARACTERISTICS:

• Histologically confirmed primary endometrial carcinoma meeting 1 of the following criteria:

  • Stage III or IV disease according to FIGO staging criteria
  • Recurrent disease that is considered incurable

• Measurable disease

  • A lesion within a previously irradiated field is acceptable as measurable disease only if there has been clear progression since completion of radiotherapy

PATIENT CHARACTERISTICS:

• GOG performance status 0-2
• Absolute neutrophil count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Hemoglobin ≥ 9 g/dL
• Creatinine < 2.5 mg/dL OR creatinine clearance ≥ 60 mL/min
• ALT and AST ≤ 1.5 times upper limit of normal (ULN) (3 times ULN in the presence of liver metastases)
• Alkaline phosphatase ≤ 1.5 times ULN (3 times ULN in the presence of liver metastases)
• Total bilirubin ≤ 1.5 times ULN (3 times ULN in the presence of liver metastases)
• Not pregnant or nursing
• Left ventricular ejection fraction (LVEF) ≥ 50% by MUGA scan or ECHO
• No history of severe hypersensitivity reaction to doxorubicin hydrochloride liposome
• No other invasive malignancy (i.e., breast cancer) within the past 5 years except nonmelanoma skin cancer

• No cardiac disease, including any of the following:

  • Myocardial infarction within the past 6 months
  • NYHA class II-IV heart failure
  • Uncontrolled angina
  • Severe uncontrolled ventricular arrhythmias
  • Clinically significant pericardial disease
  • Acute ischemic or active conduction system abnormalities by ECHO

PRIOR CONCURRENT THERAPY:

• No prior chemotherapy
• No prior cancer therapy that would contraindicate study treatment
• No concurrent investigational agents